Serious adverse events · people with substance use disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Serious adverse events
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Serious adverse events
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · Induction of Remission in Medically Refractory Crohn's Disease
Summary of findings table ‐ Stem Cell showed no clear difference in serious Adverse Events compared with placebo or Control (low certainty).
1 finding from 1 review
Serious adverse events · people with bronchiectasis
28 days on/off antibiotic regimen showed no clear difference in serious adverse events compared with 28 days on/off placebo regimen (low certainty).
1 finding from 1 review
OR 1 [0.68, 1.46]
Studies not reported
Low
Serious adverse events · people with bronchiectasis
14 days on/off antibiotic regimen showed no clear difference in serious adverse events compared with 28 days on/off antibiotic regimen (moderate certainty).
1 finding from 1 review
OR 0.83 [0.37, 1.86]
Studies not reported
Moderate
Serious adverse events · people with bronchiectasis
14 days on/off antibiotic regimen showed no clear difference in serious adverse events compared with 14 days on/off placebo regimen (high certainty).
1 finding from 1 review
OR 0.92 [0.63, 1.33]
Studies not reported
High
Adverse events (during · children or adults with Types I or II HAE
C1 esterase inhibitor showed no clear difference in adverse events (during compared with placebo or active control (moderate certainty).
1 finding from 1 review
Adverse events (during · children or adults with Types I or II HAE
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (during · children or adults with Types I or II HAE
Avoralstat showed no clear difference in adverse events (during compared with placebo (low certainty).
1 finding from 1 review
Overall adverse events · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
Next‐generation ALK inhibitor showed no clear difference in overall adverse events compared with crizotinib (moderate certainty).
1 finding from 1 review
Overall adverse events · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
ALK inhibitor showed no clear difference in overall adverse events compared with any cytotoxic chemotherapy (low certainty).
1 finding from 1 review
Serious adverse events · children with Hirschsprung's disease (HD)
1 finding from 1 review
Serious adverse events · people with active UC
1 finding from 1 review
Serious adverse events · people with active UC
1 finding from 1 review
Serious adverse events · Patients with quiescent ulcerative colitis
1 finding from 1 review
Serious adverse events · of active and inactive people with ulcerative colitis
1 finding from 1 review
Serious adverse events · people with active UC
Antibiotics showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review